1. Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial. Issue 8 (6th April 2014) Authors: Nitti, V. W.; Chapple, C. R.; Walters, C.; Blauwet, M. B.; Herschorn, S.; Milsom, I.; Auerbach, S.; Radziszewski, P. Journal: International journal of clinical practice Issue: Volume 68:Issue 8(2014) Page Start: 972 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗